BGI, the world’s largest rapid gene sequencing center, in Shenzhen, China, is on a quest to discover the genes governing human intelligence.
Separately, China’s Shenzhen SiBiono Gene-Tech introduced the world’s first gene therapy drug, Gendicine, for head and neck cancer, attracting foreign and Chinese patients eager for treatment.
This month, Beijing-based Sinovac Biotech announced a successful late-stage trial of a hand, foot and mouth disease vaccine that may soon add to the company’s roster of vaccines for hepatitis, prevalent among Chinese.
To read the full, original article click on this link: What’s Driving China’s Biopharmaceutical Boom? - Knowledge@Wharton
